November 7, 2016

Verseon Corporation (“Verseon” or the “Company”)

Appointment of Corporate Brokers

Fremont, Calif.—Verseon Corporation (AIM:VSN) is pleased to announce the appointment of Cantor Fitzgerald Europe and Mirabaud Securities LLP as its corporate brokers, with immediate effect.

Cenkos Securities acts as the Company’s Nominated Adviser and Broker.

-Ends-

For further information please contact:

Verseon Corporation +1 (510) 225 9000
Arthur Shmurun / Amy Thai
   
Cenkos Securities (NOMAD and Broker) +44 (0) 20 7397 8900
Mark Connelly / Steve Cox  
   
Cantor Fitzgerald Europe (Joint Broker) +44 (0) 20 7894 7000
Marc Milmo / Phil Davies / Callum Butterfield  
   
Mirabaud Securities LLP (Joint Broker) +44 (0) 20 7321 2508
Peter Krens  
   

Financial and business media enquiries:

Buchanan Communications Ltd (PR Advisors) +44 (0) 20 7466 5000
Henry Harrison-Topham / Sophie Cowles

About Verseon

Verseon Corporation is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and oncology.

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen